戴德梁行：2021_上海生物医药产业生态报告-英文_16页_27mb

Summary of Shanghai's Biopharmaceutical Industry Environment Report (2021)

Core Content

This report provides an overview of the global and Chinese biopharmaceutical markets, with a focus on Shanghai's position and development prospects in the industry. It highlights the growth trends, policy support, R&D investment, and competitive landscape of the biopharmaceutical sector in Shanghai.

Main Points

Global Biopharmaceutical Market Overview

• The global pharmaceutical and medical device market has expanded significantly in recent years.
• Increased healthcare awareness, rising incomes, and integration with technology are expected to drive further growth.
• The global market size is projected to continue expanding, with a strong emphasis on innovation and quality in the industry.

China Biopharmaceutical Market Overview

• Foreign biopharmaceutical companies began entering the Chinese mainland in the 1980s, enriching the drug market and accelerating the domestic industry.
• China's biopharmaceutical industry has seen substantial growth, with a market size of about RMB3.57 trillion in 2021.
• The market is expected to exceed RMB4 trillion in 2022, with continued growth anticipated.
• China aims to become one of the world's most mature and important biopharmaceutical markets.

Shanghai Biopharmaceutical Market Overview

• Shanghai has been developing its biopharmaceutical industry since 2009, with a complete industrial chain from R&D to sales.
• The city has a "1+5+X" spatial layout for biopharmaceutical industrial parks.
• By 2020, the industry's total economic volume reached RMB600 billion, nearly six times that of 2008.
• Shanghai is home to the highest concentration of foreign biopharmaceutical enterprises in China, with around 41 of the 57 world-renowned companies having a presence.
• The city has a strong talent pool and favorable policies that support the biopharmaceutical industry.

Comparative Study of Biopharmaceutical Industry Centers

• Shanghai is compared to other global and Chinese biopharmaceutical centers, including Switzerland, the US (Boston and San Francisco Bay Area), and cities like Beijing, Guangzhou, Shenzhen, Wuhan, and Chengdu.
• Shanghai leads in R&D investment among Chinese cities, with RMB8.7 billion in 2020.
• The city also ranks second in employment attractiveness for Chinese talent returning from overseas.
• Shanghai's financial support for biopharmaceutical R&D is robust, with varying levels of funding for different stages of development.

SWOT Analysis of Shanghai's Biopharmaceutical Industry

• Strengths: Strong clinical research capability, complete industrial chain, high concentration of foreign enterprises, and a favorable financing environment.
• Weaknesses: Lack of production bases for active pharmaceutical ingredients (APIs) and high industrial land prices.
• Opportunities: Favorable policy environment, effective control of the COVID-19 epidemic, and technological opportunities in 5G, 6G, and AI.
• Threats: Intense competition from other cities in China that are investing heavily in similar fields.

Outlook for the Shanghai Biopharmaceutical Market

• With strong political and capital support, Shanghai aims to promote R&D development across all biopharmaceutical sectors.
• The city plans to establish a "Made in Shanghai" brand, focusing on innovative medicines and medical devices.
• It is expected to solidify its position as a world-class biopharmaceutical industry center.

Key Information

• Market Growth: The global pharmaceutical and medical device market is expected to grow further due to increased healthcare awareness and technological integration.
• Shanghai's Economic Contribution: In 2020, the Shanghai biopharmaceutical industry reached RMB600 billion, showing significant growth since 2008.
• R&D Investment: In 2020, Shanghai's domestic listed company R&D investment in biopharmaceuticals was RMB8.7 billion, the highest in China.
• Policy Support: Shanghai offers generous financial incentives for biopharmaceutical R&D, including up to 40% of R&D investment for clinical trials and up to 30% for overseas market registration.
• Talent Attraction: Shanghai is a top destination for Chinese talent returning from overseas, with strong employment attractiveness.
• Foreign Investment: Shanghai is home to the highest concentration of foreign biopharmaceutical enterprises in China, contributing to its global competitiveness.
• Financing Trends: In 2020, Shanghai accounted for 14 of the top 15 biopharmaceutical financing events in China, with a total financing amount of RMB8.4 billion.

Conclusion

Shanghai is a key player in the global biopharmaceutical industry, with a well-developed industrial chain, strong R&D capabilities, and favorable policies. Despite challenges such as high land costs and a lack of API production, the city continues to benefit from a robust financing environment, a growing talent pool, and technological advancements. The outlook for Shanghai's biopharmaceutical market is positive, with the city aiming to become a world-class center through continued investment and innovation.